文献速递心力衰竭与心肌病

Medicare对心衰四联疗法的覆盖与自付费用

Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

该研究分析了2020年全部4,068个Medicare处方药计划对HFrEF四联疗法的覆盖与自付费用。四联疗法30天中位自付费用为94美元,年自付费用为2,217美元,显著高于仿制药方案的3美元(30天)。多数计划要求较高层级共付,四联疗法对许多Medicare患者可能难以负担。

要点

  • 四联疗法30天中位自付费用94美元,年自付费用2,217美元
  • 仿制药方案30天中位自付费用仅3美元,费用差异显著
  • 99.1%计划对ARNI、98.5%计划对至少一种SGLT2i要求≥3级共付

核心结论

  • Medicare处方药计划通过共付限制四联疗法覆盖,其自付费用显著高于仿制药方案,许多HFrEF患者可能难以负担。

研究设计与样本

  • 研究评估了2020年全部4,068个Medicare处方药计划的共付、事先授权和阶梯治疗,并基于Part D标准福利计算标准覆盖期和年度自付费用。

主要发现

  • 99.1%的计划对ARNI要求≥3级共付,98.5%的计划对至少一种SGLT2i要求≥3级共付。
  • 仅ARNI需要事先授权(24.3%的计划),阶梯治疗仅见于SGLT2i(5.4%)和依普利酮(0.8%)。
  • 四联疗法30天标准覆盖期中位自付费用为94美元(IQR: 84-100),其中ARNI为47美元(IQR: 40-47),SGLT2i为45美元(IQR: 40-47)。
  • 四联疗法年中位自付费用为2,217美元(IQR: 1,956-2,579),排除SGLT2i时为1,319美元(IQR: 1,067-1,675),以ACEI或ARB替代ARNI时为1,322美元(IQR: 1,025-1,588)。
  • 仿制药方案30天中位自付费用为3美元(IQR: 0-9)。

关键数值与推荐

  • 四联疗法30天中位自付费用94美元(IQR: 84-100),年中位自付费用2,217美元(IQR: 1,956-2,579)。
  • 仿制药方案30天中位自付费用3美元(IQR: 0-9)。

临床怎么用

  • 处方四联疗法时应评估Medicare患者的自付费用负担,仿制药方案费用显著更低。
  • 需关注ARNI的事先授权和SGLT2i的阶梯治疗对用药可及性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors (SGLT2i), known as quadruple therapy, are recommended for patients with heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: This study sought to determine Medicare coverage and out-of-pocket (OOP) costs of quadruple therapy and regimens excluding ARNI or SGLT2i. METHODS: This study assessed cost sharing, prior authorization, and step therapy in all 4,068 Medicare prescription drug plans in 2020. OOP costs were determined during the standard coverage period and annually based on the Medicare Part D standard benefit, inclusive of deductible, standard coverage, coverage gap, and catastrophic coverage. RESULTS: Tier ≥3 cost sharing was required by 99.1% of plans for ARNI and 98.5% for at least 1 SGLT2i. Only ARNI required prior authorization (24.3% of plans), and step therapy was required only for SGLT2is (5.4%) and eplerenone (0.8%). The median 30-day standard coverage OOP cost of quadruple therapy was $94 (IQR: $84-$100), including $47 (IQR: $40-$47) for ARNI and $45 (IQR: $40-$47) for SGLT2i. The median annual OOP cost of quadruple therapy was $2,217 (IQR: $1,956-$2,579) compared with $1,319 (IQR: $1,067-$1,675) when excluding SGLT2i and $1,322 (IQR: $1,025-$1,588) when including SGLT2i and substituting an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for ARNI. The median 30-day OOP cost of generic regimens was $3 (IQR: $0-$9). CONCLUSIONS: Medicare drug plans restrict coverage of quadruple therapy through cost sharing, with OOP costs that are substantially higher than generic regimens. Quadruple therapy may be unaffordable for many Medicare patients with HFrEF unless medication prices and cost sharing are reduced.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Faridi, Dayoub, Ross, et al. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. J Am Coll Cardiol. 2022. PMID: 35738713. doi:10.1016/j.jacc.2022.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。